{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:04:29Z","timestamp":1793160269811,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81772797"],"award-info":[{"award-number":["81772797"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"crossref","award":["20172007"],"award-info":[{"award-number":["20172007"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ductal carcinoma in situ (DCIS) often upgrade to invasive breast cancer at surgery. The current study aimed to identify factors associated with pathological underestimation and evaluate concordance rates of biomarkers between biopsy and surgery. Patients diagnosed with DCIS at needle biopsy from 2009 to 2020 were retrospectively reviewed. Univariate and multivariate analyses were performed to identify factors associated with pathological underestimation. Concordance rates between paired biopsy samples and surgical specimens were evaluated. A total of 735 patients with pure DCIS at biopsy were included, and 392 patients (53.3%) underwent pathological underestimation at surgery. Multivariate analysis demonstrated that tumor size\u2009&gt;\u20095.0\u00a0cm [odds ratio (OR) 1.79], MRI BI-RADS\u2009\u2265\u20095 categories (OR 2.03), and high nuclear grade (OR 2.01) were significantly associated with pathological underestimation. Concordance rates of ER, PR, HER2 status and Ki-67 between biopsy and surgery were 89.6%, 91.9%, 94.8%, and 76.4% in lesions without pathological underestimation, and were 86.4%, 93.2%, 98.2% and 76.3% for in situ components in lesions with pathological underestimation. Meanwhile, in situ components and invasive components at surgery had concordance rates of 92.9%, 93.8%, 97.4%, and 86.5% for those biomarkers, respectively. In conclusion, lesions diagnosed as DCIS at biopsy have a high rate of pathological underestimation, which was associated with larger tumor size, higher MRI BI-RADS category, and higher nuclear grade. High concordances were found in terms of ER, PR, and HER2 status evaluation between biopsy and surgery, regardless of the pathological underestimation.<\/jats:p>","DOI":"10.1038\/s41598-022-06206-7","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:04:57Z","timestamp":1644404697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy"],"prefix":"10.1038","volume":"12","author":[{"given":"Hemei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"6206_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/his.12796","author":"J-MB Pang","year":"2016","unstructured":"Pang, J.-M.B., Gorringe, K. L. & Fox, S. B. Ductal carcinoma in situ: Update on risk assessment and management. Histopathology https:\/\/doi.org\/10.1111\/his.12796 (2016).","journal-title":"Histopathology"},{"key":"6206_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10549-020-05690-7","volume":"182","author":"S Ramzi","year":"2020","unstructured":"Ramzi, S., Najeeb, E., Coulthard, J. & Jenkins, S. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?. Breast Cancer Res. Treat. 182, 47\u201354. https:\/\/doi.org\/10.1007\/s10549-020-05690-7 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"6206_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","volume":"1","author":"SA Narod","year":"2015","unstructured":"Narod, S. A., Iqbal, J., Giannakeas, V., Sopik, V. & Sun, P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 1, 888\u2013896. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2510 (2015).","journal-title":"JAMA Oncol."},{"key":"6206_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32362","volume":"146","author":"MR Van Bockstal","year":"2020","unstructured":"Van Bockstal, M. R., Agahozo, M. C., Koppert, L. B. & van Deurzen, C. H. M. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int. J. Cancer 146, 1189\u20131197. https:\/\/doi.org\/10.1002\/ijc.32362 (2020).","journal-title":"Int. J. Cancer"},{"key":"6206_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.11102368","volume":"260","author":"ME Brennan","year":"2011","unstructured":"Brennan, M. E. et al. Ductal carcinoma in situ at core-needle biopsy: Meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260, 119\u2013128. https:\/\/doi.org\/10.1148\/radiol.11102368 (2011).","journal-title":"Radiology"},{"key":"6206_CR6","doi-asserted-by":"publisher","first-page":"e805","DOI":"10.1016\/j.clbc.2018.04.011","volume":"18","author":"MT D\u00f3ria","year":"2018","unstructured":"D\u00f3ria, M. T. et al. Development of a model to predict invasiveness in ductal carcinoma in situ diagnosed by percutaneous biopsy-original study and critical evaluation of the literature. Clin. Breast Cancer 18, e805\u2013e812. https:\/\/doi.org\/10.1016\/j.clbc.2018.04.011 (2018).","journal-title":"Clin. Breast Cancer"},{"key":"6206_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2016.02.014","volume":"27","author":"SC Doebar","year":"2016","unstructured":"Doebar, S. C. et al. Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen. Breast 27, 15\u201321. https:\/\/doi.org\/10.1016\/j.breast.2016.02.014 (2016).","journal-title":"Breast"},{"key":"6206_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.breast.2012.06.012","volume":"21","author":"J Kim","year":"2012","unstructured":"Kim, J. et al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast 21, 641\u2013645. https:\/\/doi.org\/10.1016\/j.breast.2012.06.012 (2012).","journal-title":"Breast"},{"key":"6206_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s12885-020-07001-1","volume":"20","author":"K Takada","year":"2020","unstructured":"Takada, K. et al. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ. BMC Cancer 20, 513. https:\/\/doi.org\/10.1186\/s12885-020-07001-1 (2020).","journal-title":"BMC Cancer"},{"key":"6206_CR10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ejso.2019.01.015","volume":"45","author":"LC Marques","year":"2019","unstructured":"Marques, L. C. et al. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!. Eur. J. Surg. Oncol. 45, 1152\u20131155. https:\/\/doi.org\/10.1016\/j.ejso.2019.01.015 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"6206_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1015-9584(10)60013-9","volume":"33","author":"MYP Chan","year":"2010","unstructured":"Chan, M. Y. P. & Lim, S. Predictors of invasive breast cancer in ductal carcinoma in situ initially diagnosed by core biopsy. Asian J. Surg. 33, 76\u201382. https:\/\/doi.org\/10.1016\/S1015-9584(10)60013-9 (2010).","journal-title":"Asian J. Surg."},{"key":"6206_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41416-018-0276-6","volume":"119","author":"CJC Meurs","year":"2018","unstructured":"Meurs, C. J. C. et al. A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: Based on 2892 biopsies and 589 invasive cancers. Br. J. Cancer 119, 1155\u20131162. https:\/\/doi.org\/10.1038\/s41416-018-0276-6 (2018).","journal-title":"Br. J. Cancer"},{"key":"6206_CR13","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00330-011-2357-2","volume":"22","author":"M Goto","year":"2012","unstructured":"Goto, M. et al. The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy. Eur. Radiol. 22, 1255\u20131264. https:\/\/doi.org\/10.1007\/s00330-011-2357-2 (2012).","journal-title":"Eur. Radiol."},{"key":"6206_CR14","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1259\/bjr\/30974918","volume":"85","author":"YJ Suh","year":"2012","unstructured":"Suh, Y. J. et al. Comparison of the underestimation rate in cases with ductal carcinoma in situ at ultrasound-guided core biopsy: 14-gauge automated core-needle biopsy vs 8- or 11-gauge vacuum-assisted biopsy. Br. J. Radiol. 85, e349\u2013e356. https:\/\/doi.org\/10.1259\/bjr\/30974918 (2012).","journal-title":"Br. J. Radiol."},{"key":"6206_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/jso.23273","volume":"107","author":"HS Park","year":"2013","unstructured":"Park, H. S. et al. Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy. J. Surg. Oncol. 107, 388\u2013392. https:\/\/doi.org\/10.1002\/jso.23273 (2013).","journal-title":"J. Surg. Oncol."},{"key":"6206_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jso.24037","volume":"112","author":"T Kondo","year":"2015","unstructured":"Kondo, T. et al. A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast. J. Surg. Oncol. 112, 476\u2013480. https:\/\/doi.org\/10.1002\/jso.24037 (2015).","journal-title":"J. Surg. Oncol."},{"key":"6206_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10549-019-05333-6","volume":"177","author":"A Ponti","year":"2019","unstructured":"Ponti, A. et al. Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: Evidence from an international multi-centre study. Breast Cancer Res. Treat. 177, 761\u2013765. https:\/\/doi.org\/10.1007\/s10549-019-05333-6 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"6206_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/tbj.12201","volume":"19","author":"DJ Wisner","year":"2013","unstructured":"Wisner, D. J. et al. Features of occult invasion in biopsy-proven DCIS at breast MRI. Breast J. 19, 650\u2013658. https:\/\/doi.org\/10.1111\/tbj.12201 (2013).","journal-title":"Breast J."},{"key":"6206_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.acra.2019.09.025","volume":"27","author":"LR Lamb","year":"2020","unstructured":"Lamb, L. R., Lehman, C. D., Oseni, T. O. & Bahl, M. Ductal carcinoma in situ (DCIS) at breast MRI: Predictors of upgrade to invasive carcinoma. Acad. Radiol. 27, 1394\u20131399. https:\/\/doi.org\/10.1016\/j.acra.2019.09.025 (2020).","journal-title":"Acad. Radiol."},{"key":"6206_CR20","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1148\/rg.336125055","volume":"33","author":"HI Greenwood","year":"2013","unstructured":"Greenwood, H. I. et al. Ductal carcinoma in situ of the breasts: Review of MR imaging features. Radiographics 33, 1569\u20131588. https:\/\/doi.org\/10.1148\/rg.336125055 (2013).","journal-title":"Radiographics"},{"issue":"62","key":"6206_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1590\/1806-9282.62.05.421","volume":"1992","author":"GM Badan","year":"2016","unstructured":"Badan, G. M. et al. Ductal carcinoma in situ of the breast: Evaluation of main presentations on magnetic resonance imaging compared with findings on mammogram and histology. Rev. Assoc. Med. Bras. 1992(62), 421\u2013427. https:\/\/doi.org\/10.1590\/1806-9282.62.05.421 (2016).","journal-title":"Rev. Assoc. Med. Bras."},{"key":"6206_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.pathol.2019.07.005","volume":"51","author":"SS Badve","year":"2019","unstructured":"Badve, S. S. & G\u00f6kmen-Polar, Y. Ductal carcinoma in situ of breast: Update 2019. Pathology 51, 563\u2013569. https:\/\/doi.org\/10.1016\/j.pathol.2019.07.005 (2019).","journal-title":"Pathology"},{"key":"6206_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10549-018-4860-5","volume":"171","author":"NK Stout","year":"2018","unstructured":"Stout, N. K. et al. Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res. Treat. 171, 777\u2013781. https:\/\/doi.org\/10.1007\/s10549-018-4860-5 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"6206_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.breast.2010.12.007","volume":"20","author":"V Lorgis","year":"2011","unstructured":"Lorgis, V. et al. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 20, 284\u2013287. https:\/\/doi.org\/10.1016\/j.breast.2010.12.007 (2011).","journal-title":"Breast"},{"key":"6206_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1373\/clinchem.2013.207183","volume":"60","author":"JMS Bartlett","year":"2014","unstructured":"Bartlett, J. M. S., Nofech-Moses, S. & Rakovitch, E. Ductal carcinoma in situ of the breast: Can biomarkers improve current management?. Clin. Chem. 60, 60\u201367. https:\/\/doi.org\/10.1373\/clinchem.2013.207183 (2014).","journal-title":"Clin. Chem."},{"key":"6206_CR26","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1111\/j.1349-7006.2010.01630.x","volume":"101","author":"K Tamaki","year":"2010","unstructured":"Tamaki, K. et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci. 101, 2074\u20132079. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01630.x (2010).","journal-title":"Cancer Sci."},{"key":"6206_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s10549-012-1990-z","volume":"134","author":"X Chen","year":"2012","unstructured":"Chen, X., Yuan, Y., Gu, Z. & Shen, K. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: A meta-analysis. Breast Cancer Res. Treat. 134, 957\u2013967. https:\/\/doi.org\/10.1007\/s10549-012-1990-z (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"6206_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/1471-2407-13-390","volume":"13","author":"X Chen","year":"2013","unstructured":"Chen, X. et al. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer 13, 390. https:\/\/doi.org\/10.1186\/1471-2407-13-390 (2013).","journal-title":"BMC Cancer"},{"key":"6206_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1186\/s12885-015-1853-1","volume":"15","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. BMC Cancer 15, 822. https:\/\/doi.org\/10.1186\/s12885-015-1853-1 (2015).","journal-title":"BMC Cancer"},{"key":"6206_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/archsurg.133.4.383","volume":"133","author":"SO Hofer","year":"1998","unstructured":"Hofer, S. O., Shrayer, D., Reichner, J. S., Hoekstra, H. J. & Wanebo, H. J. Wound-induced tumor progression: A probable role in recurrence after tumor resection. Arch. Surg. 133, 383\u2013389 (1998).","journal-title":"Arch. Surg."},{"key":"6206_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.21037\/atm.2019.08.16","volume":"7","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. The prognostic significance of co-existence ductal carcinoma in invasive ductal breast cancer: A large population-based study and a matched case-control analysis. Ann. Transl. Med. 7, 484. https:\/\/doi.org\/10.21037\/atm.2019.08.16 (2019).","journal-title":"Ann. Transl. Med."},{"key":"6206_CR32","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00432-019-02930-2","volume":"145","author":"CW Goh","year":"2019","unstructured":"Goh, C. W. et al. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC\/DCIS) versus pure invasive ductal carcinoma (IDC): A comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. J. Cancer Res. Clin. Oncol. 145, 1877\u20131886. https:\/\/doi.org\/10.1007\/s00432-019-02930-2 (2019).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"6206_CR33","doi-asserted-by":"publisher","first-page":"e13055","DOI":"10.1097\/MD.0000000000013055","volume":"97","author":"Z-B Wan","year":"2018","unstructured":"Wan, Z.-B. et al. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion. Medicine 97, e13055. https:\/\/doi.org\/10.1097\/MD.0000000000013055 (2018).","journal-title":"Medicine"},{"key":"6206_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.molonc.2010.06.007","volume":"4","author":"AA Muggerud","year":"2010","unstructured":"Muggerud, A. A. et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol. Oncol. 4, 357\u2013368. https:\/\/doi.org\/10.1016\/j.molonc.2010.06.007 (2010).","journal-title":"Mol. Oncol."},{"key":"6206_CR35","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1158\/0008-5472.CAN-05-4610","volume":"66","author":"CS Schuetz","year":"2006","unstructured":"Schuetz, C. S. et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 66, 5278\u20135286 (2006).","journal-title":"Cancer Res."},{"key":"6206_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.rcl.2014.02.008","volume":"52","author":"CL Mercado","year":"2014","unstructured":"Mercado, C. L. BI-RADS update. Radiol. Clin. North Am. 52, 481\u2013487. https:\/\/doi.org\/10.1016\/j.rcl.2014.02.008 (2014).","journal-title":"Radiol. Clin. North Am."},{"key":"6206_CR37","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984 (2013).","journal-title":"J. Clin. Oncol."},{"key":"6206_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan, P. H. et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology 77, 181\u2013185. https:\/\/doi.org\/10.1111\/his.14091 (2020).","journal-title":"Histopathology"},{"key":"6206_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/PAI.0b013e3181acaded","volume":"18","author":"MC Schorr","year":"2010","unstructured":"Schorr, M. C., Pedrini, J. L., Savaris, R. F. & Zettler, C. G. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?. Appl. Immunohistochem. Mol. Morphol. 18, 51\u201354. https:\/\/doi.org\/10.1097\/PAI.0b013e3181acaded (2010).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"6206_CR40","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates, A. S. et al. Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 26, 1533\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdv221 (2015).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06206-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06206-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06206-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:08:38Z","timestamp":1669327718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06206-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6206"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06206-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"4 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2169"}}